Constance Jacob, APRN
Nurse Practitioner · Wichita, KSNPI 1639729726
Payments from drug & device makers
Across 793 payments — averaging $82.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$49K
- E.r. Squibb & Sons, L.L.C.$7K
- Otsuka America Pharmaceutical, Inc.$2K
- Johnson & Johnson$1K
- Neurocrine Biosciences, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$903
- plus $4K from 15 others
What the payments were for
- Consulting fees$6,0569%
- Speaking & faculty fees$41,78664%
- Travel & lodging$4,0576%
- Food & beverage$13,21220%
- Education$1360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 181 | $48,891 |
| E.r. Squibb & Sons, L.L.C. | 28 | $7,249 |
| Otsuka America Pharmaceutical, Inc. | 120 | $1,847 |
| Johnson & Johnson | 89 | $1,476 |
| Neurocrine Biosciences, Inc. | 80 | $1,076 |
| Teva Pharmaceuticals USA, Inc. | 51 | $903 |
| Alkermes, Inc. | 51 | $794 |
| Vanda Pharmaceuticals Inc. | 38 | $749 |
| AbbVie | 40 | $556 |
| Lundbeck LLC | 31 | $475 |
| Axsome Therapeutics, Inc. | 19 | $295 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $246 |
| Sunovion Pharmaceuticals Inc. | 14 | $184 |
| Indivior Inc. | 14 | $175 |
| Eisai Inc. | 5 | $101 |
| Merck | 4 | $54 |
| Supernus Pharmaceuticals, Inc. | 3 | $50 |
| Biogen | 2 | $45 |
| Avanir Pharmaceuticals, Inc. | 3 | $39 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Noven Therapeutics, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$46,259
- COBENFY$2,794
- INVEGA SUSTENNA$336
- REXULTI$126
How this compares
$65,247 in reported general payments places this provider in the 95th percentile of 1,326 nurse practitioner providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 89 | $266,229 |
| RexultiBrexpiprazole | 114 | $115,396 |
| CaplytaLumateperone Tosylate | 79 | $112,367 |
| VraylarCariprazine Hcl | 42 | $67,379 |
| AustedoDeutetrabenazine | 13 | $60,040 |
| FanaptIloperidone | 12 | $26,316 |
| Paliperidone ErPaliperidone | 40 | $17,032 |
| Clozapine | 125 | $15,077 |
| Lurasidone Hcl | 32 | $11,146 |
| TrintellixVortioxetine Hydrobromide | 22 | $10,415 |
| Ramelteon | 24 | $6,257 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 81 | $5,032 |
| Olanzapine | 145 | $4,735 |
| Divalproex Sodium ErDivalproex Sodium | 61 | $3,888 |
| Aripiprazole | 122 | $3,574 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $1,476 | $266,22989 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,847 | $115,396114 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $48,891 | $112,36779 claims |
| AbbVieVraylar | $556 | $67,37942 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $903 | $60,04013 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $749 | $26,31612 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $246 | $10,41522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,326 nurse practitioner providers in Kansas.
Other nurse practitioner in Wichita
- Catherine PowellWichita$50K
- Darine JamaleddineWichita$15K
- Krystal MitchellWichita$13K
- Jolene GrotheWichita$11K
- Christina StantonWichita$11K
- Sarah RookerWichita$10K
- Ayman HamadWichita$9K
- Amanda MogoiWichita$9K
- Jill AugustineWichita$8K
- Rebecca WernliWichita$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.